Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07009132 · ClinicalTrials.gov registry record
Cholate Clearance in Fontan and Heart Failure
A clinical trial of Right Heart Failure and Fontan, sponsored by HepQuant.
- Recruiting
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT07009132 is a study of Right Heart Failure and Fontan that is actively recruiting participants, run by HepQuant. The registered enrollment target is 75 participants, below the 695-participant average among 4 other Right Heart Failure trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07009132, a study of Right Heart Failure and Fontan, is actively recruiting participants, sponsored by HepQuant.
- RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to use the HepQuant dual cholate clearance assay, which has been shown to measure liver function in people with known chronic liver conditions, to assess severity of Fontan-associated liver disease (FALD). This study aims to understand the role impaired blood flow to the liver plays in liver function in Fontan patients compared to patients with right heart failure and healthy controls. The study will also determine whether cholate clearance is a good measure to use in this population, and whether it will be able to predict clinical outcomes. Participants will undergo a HepQuant dual cholate clearance assay and a cardiac magnetic resonance imaging (MRI) at the beginning of the study, and then data on health status will be collected for 5 years.
Conditions Studied
Interventions
- RADIATION MRI
- DEVICE Dual cholate clearance assay
Study Locations (1)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-08-04 |
| Est. Completion | 2031-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07009132
The ClinicalTrials.gov registry entry for NCT07009132 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 695-participant average among 4 other Right Heart Failure trials with a reported enrollment target (89% lower). The listed sponsor is HepQuant, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Right Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which MRI is the first listed.
NCT07009132 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07009132 about?
NCT07009132 is a clinical study titled "Cholate Clearance in Fontan and Heart Failure". The goal of this study is to use the HepQuant dual cholate clearance assay, which has been shown to measure liver function in people with known chronic liver conditions, to assess severity of Fontan-associated liver disease (FALD). This study aims to understand the role impaired blood flow to the l...
What is the current status of trial NCT07009132?
This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2025-08-04. Estimated completion is 2031-12.
What conditions does trial NCT07009132 study?
This clinical trial studies the following conditions: Right Heart Failure, Fontan.
What interventions are being tested in trial NCT07009132?
The interventions under investigation include: MRI (RADIATION), Dual cholate clearance assay (DEVICE).
Who is sponsoring clinical trial NCT07009132?
This trial is sponsored by HepQuant, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07009132 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Right Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Repurposing Valsartan May Protect Against Pulmonary Hypertension
RECRUITING · Phase 2
-
Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future
RECRUITING
-
Repository of Phase Signals for Pulmonary Hypertension Algorithm Development
ACTIVE NOT RECRUITING · NA
-
Treatment of Tricuspid Valve Regurgitation in Patients Undergoing Left Ventricular Assist Device Implantation Study
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.